Matches in SemOpenAlex for { <https://semopenalex.org/work/W4322757675> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W4322757675 endingPage "228" @default.
- W4322757675 startingPage "225" @default.
- W4322757675 abstract "Purpose: To compare the duration of vascular endothelial growth factor (VEGF) suppression in the aqueous humor of macaque eyes after intravitreal injection of brolucizumab and aflibercept. Methods: Clinical dose of intravitreal brolucizumab (IVBr; 6.0 mg/50 μL) or intravitreal aflibercept (IVA; 2 mg/50 μL) was injected into the right eye of each of 8 macaques. Aqueous humor samples (150 μL) from both eyes were obtained just before injection and on days 1, 3, 7, 14, 21, 28, 42, 56, 84, and 112 after IVBr injection or IVA injection. VEGF concentrations were measured using enzyme-linked immunosorbent assays. Results: In the injected eyes, the mean VEGF suppression durations (range) were 4.9 (3-8) weeks for IVBr injection and 6.8 (6-8) weeks for IVA injection (P = 0.04). The VEGF concentrations returned to the preinjection level in the aqueous humor at 12 weeks both after IVBr and IVA injection. In the noninjected fellow eyes, the aqueous VEGF concentrations had decreased least at 1 day after IVBr injection and at 3 days after IVA injection, but were still detectable. The VEGF concentrations in the fellow eyes returned to the preinjection level in the aqueous humor at 1 week after IVBr injection and at 2 weeks after IVA injection. Conclusions: The duration of VEGF suppression in the aqueous humor after IVBr injection may be shorter than that after IVA injection, which may be related with clinical usage." @default.
- W4322757675 created "2023-03-03" @default.
- W4322757675 creator A5001491452 @default.
- W4322757675 creator A5011878231 @default.
- W4322757675 creator A5022180167 @default.
- W4322757675 creator A5024057615 @default.
- W4322757675 creator A5031801451 @default.
- W4322757675 creator A5054359617 @default.
- W4322757675 date "2023-04-01" @default.
- W4322757675 modified "2023-10-16" @default.
- W4322757675 title "Duration of Vascular Endothelial Growth Factor Suppression After Intravitreal Injection of Brolucizumab and Aflibercept in Macaque Eyes" @default.
- W4322757675 cites W1990201092 @default.
- W4322757675 cites W2005365354 @default.
- W4322757675 cites W2073888700 @default.
- W4322757675 cites W2082572493 @default.
- W4322757675 cites W2461948703 @default.
- W4322757675 cites W2743489810 @default.
- W4322757675 cites W2778081976 @default.
- W4322757675 cites W2936430874 @default.
- W4322757675 cites W2991331877 @default.
- W4322757675 cites W3005138496 @default.
- W4322757675 cites W3126211076 @default.
- W4322757675 cites W3128386949 @default.
- W4322757675 cites W3153102681 @default.
- W4322757675 cites W3161004646 @default.
- W4322757675 doi "https://doi.org/10.1089/jop.2022.0160" @default.
- W4322757675 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36862540" @default.
- W4322757675 hasPublicationYear "2023" @default.
- W4322757675 type Work @default.
- W4322757675 citedByCount "0" @default.
- W4322757675 crossrefType "journal-article" @default.
- W4322757675 hasAuthorship W4322757675A5001491452 @default.
- W4322757675 hasAuthorship W4322757675A5011878231 @default.
- W4322757675 hasAuthorship W4322757675A5022180167 @default.
- W4322757675 hasAuthorship W4322757675A5024057615 @default.
- W4322757675 hasAuthorship W4322757675A5031801451 @default.
- W4322757675 hasAuthorship W4322757675A5054359617 @default.
- W4322757675 hasConcept C118487528 @default.
- W4322757675 hasConcept C126322002 @default.
- W4322757675 hasConcept C141071460 @default.
- W4322757675 hasConcept C167734588 @default.
- W4322757675 hasConcept C2776694085 @default.
- W4322757675 hasConcept C2777025900 @default.
- W4322757675 hasConcept C2777802072 @default.
- W4322757675 hasConcept C2778749236 @default.
- W4322757675 hasConcept C2993390227 @default.
- W4322757675 hasConcept C42219234 @default.
- W4322757675 hasConcept C71924100 @default.
- W4322757675 hasConceptScore W4322757675C118487528 @default.
- W4322757675 hasConceptScore W4322757675C126322002 @default.
- W4322757675 hasConceptScore W4322757675C141071460 @default.
- W4322757675 hasConceptScore W4322757675C167734588 @default.
- W4322757675 hasConceptScore W4322757675C2776694085 @default.
- W4322757675 hasConceptScore W4322757675C2777025900 @default.
- W4322757675 hasConceptScore W4322757675C2777802072 @default.
- W4322757675 hasConceptScore W4322757675C2778749236 @default.
- W4322757675 hasConceptScore W4322757675C2993390227 @default.
- W4322757675 hasConceptScore W4322757675C42219234 @default.
- W4322757675 hasConceptScore W4322757675C71924100 @default.
- W4322757675 hasIssue "3" @default.
- W4322757675 hasLocation W43227576751 @default.
- W4322757675 hasLocation W43227576752 @default.
- W4322757675 hasOpenAccess W4322757675 @default.
- W4322757675 hasPrimaryLocation W43227576751 @default.
- W4322757675 hasRelatedWork W1444397246 @default.
- W4322757675 hasRelatedWork W2002051597 @default.
- W4322757675 hasRelatedWork W2030557023 @default.
- W4322757675 hasRelatedWork W2368339077 @default.
- W4322757675 hasRelatedWork W2461948703 @default.
- W4322757675 hasRelatedWork W4224443350 @default.
- W4322757675 hasRelatedWork W4243304339 @default.
- W4322757675 hasRelatedWork W4312067102 @default.
- W4322757675 hasRelatedWork W783581305 @default.
- W4322757675 hasRelatedWork W784061990 @default.
- W4322757675 hasVolume "39" @default.
- W4322757675 isParatext "false" @default.
- W4322757675 isRetracted "false" @default.
- W4322757675 workType "article" @default.